GetWiki

{{short description|Chemical compound}}{{Drugbox| IUPAC_name = (3aR,7S,10S,12R,21E,24aR)-7-tert-Butyl-N-{(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19] [1,10,17,3,6]trioxadiazacyclonon adecino[11,12-b]quinoxaline-10-carboxamide| image = Glecaprevir.svg| width =| tradename = Mavyret (combination with pibrentasvir)| Drugs.com =| licence_US =| pregnancy_AU = | pregnancy_US =| pregnancy_category =| legal_AU = | legal_CA = | legal_UK = | legal_US =| legal_status =

Oral administration>By mouth| bioavailability =| protein_bound = 97.5%| metabolism = CYP3A| elimination_half-life = 6 hours| excretion = Faeces (92.1%), urine (0.7%)

correct|CAS}}| CAS_number = 1365970-03-1| ATC_prefix = None| ATC_suffix =| PubChem = 66828839| DrugBank = DB13879| ChemSpiderID = 35013015

correct|FDA}}| UNII = K6BUU8J72P| KEGG = D10814| ChEMBL =| NIAID_ChemDB =| PDB_ligand =| synonyms = ABT-493| chemical_formula =

H = 46

N=6

S=1| molecular_weight =| smiles = CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O| StdInChI = 1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1| StdInChIKey = MLSQGNCUYAMAHD-ITNVBOSISA-N}}Glecaprevir (INN,WEB, International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 76,weblink World Health Organization, 25 February 2017, 503, ) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals.NEWS,weblink ACS names its 2023 Heroes of Chemistry, August 14, 2023, 101, 26, Chemical & Engineering News, Notman, Nina, 2024-04-04,weblink 2024-03-16, It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.JOURNAL, Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J, 6, Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection, Antimicrobial Agents and Chemotherapy, 60, 3, 1546–55, December 2015, 26711747, 4775945, 10.1128/AAC.02264-15, On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.NEWS, AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C.,weblink 25 February 2017, AbbVie Inc. North Chicago, Illinois, U.S.A., December 19, 2016, en, In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.WEB,weblink Maviret: EPAR – Summary for the public, European Medicines Agency, 2017-08-17, See also Protease inhibitor (pharmacology) References {{reflist}}{{RNA antivirals}}{{antiinfective-drug-stub}}